Last reviewed · How we verify
NCT06601075
The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)
trial in Advanced Colorectal Cancer in 30 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 February 2025 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 March 2029 |
| Sites | 1 location across China |
Conditions studied
- Advanced Colorectal Cancer — all drugs for Advanced Colorectal Cancer →
Sponsor
Ruijin Hospital
Who can join
18 and older, any sex, with Advanced Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate the value of 18F-FDG and 68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Colorectal Cancer: A Landscape of New Potential Radiopharmaceuticals.
Cabitza VS, Capponi PC, Brusa I, Vincenzi F, et al · · 2026 · PMID 41807884 · DOI 10.1007/s40291-026-00839-4
Verify or expand the search:
- PubMed search for NCT06601075
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Colorectal Cancer
Currently open trials in the same condition.
- NCT07281157 — Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment · Phase 2 · recruiting
- NCT06885385 — A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Pa · Phase 2 · recruiting
- NCT06940921 — SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases · Phase 1, PHASE2 · active not recruiting
- NCT06369259 — Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in · Phase 2 · recruiting
- NCT05731336 — A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan. · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06601075 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 22 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06601075.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing